A woman with advanced Alzheimer’s disease reportedly regained parts of her memory and speech after two sessions with psilocybin-containing mushrooms, according to a case report published in Frontiers in Neuroscience.

The unnamed Japanese American woman had lived with Alzheimer’s for about ten years and faced severe functional decline for the last five, the report stated.

She had advanced dementia, limited communication, urinary incontinence, and relied on caregivers for daily living.

Researchers said the patient received two treatments — first a 5-gram oral dose of psilocybin, followed a month later by a 3-gram oral dose.

Here's What They're Not Telling You About Your Retirement

Following the initial dose, she experienced heavy sweating and hyperthermia before entering what the study described as a prolonged sleep-like state.

When she awoke roughly nineteen hours later, the woman began speaking spontaneously about her past, engaging in a long autobiographical conversation lasting several hours.

Over the next several weeks, she regained urinary continence, began walking and dressing independently, and interacted in conversation. She smiled, expressed emotion, and maintained eye contact.

After the second psilocybin session, the researchers reported even more communication, humor, facial expression, and mobility improvements, along with continued continence.

This Could Be the Most Important Video Gun Owners Watch All Year

The woman did not experience severe or lasting side effects beyond the sweating and hyperthermia described, the study noted.

The researchers emphasized that the improvements were temporary, lasting about a month, and cautioned that the findings must be interpreted carefully.

They acknowledged several limitations, including the absence of a control group or standardized neurological tests, and the lack of modern biomarkers to confirm an Alzheimer’s diagnosis.

Other neurodegenerative conditions could not be ruled out, they wrote.

Experts unaffiliated with the study urged caution. Courtney Kloske, Ph.D., of the Alzheimer’s Association, said, “Much more research is needed in larger, more representative study populations before any conclusions can be drawn about psilocybin’s safety and effectiveness.”

Dr. Marc Siegel, Fox News senior medical analyst, called the findings “intriguing but limited,” stressing the potential unpredictability of hallucinogens in people with severe mental impairment.

Both experts agreed the substance may hold value only in highly controlled research settings.

The case coincides with growing U.S. interest in psychedelics for medical therapy. Oregon began licensing psilocybin centers in 2023, and Colorado and New Mexico introduced regulated programs in 2025.

Despite state-level initiatives, the compound remains federally illegal and is not approved by the Food and Drug Administration for Alzheimer’s or any dementia-related treatment.

We all hope the case will inspire future research into how psilocybin could interact with brain function in neurodegenerative disease.